REAL-WORLD DATA
AI-POWERED ANALYTICS
DIGITAL SOLUTIONS

Behavioral health, reinvented

Solving the defining challenge of our generation

Holmusk is building the largest real-world evidence platform, starting with behavioral health. Combining a leading behavioral health database with AI-powered analytics and digital solutions, we are advancing the frontier of evidence generation and fueling innovation.

Back to top
Contact us
What We Do

Real-World Evidence for

Real-World impact

Real-world evidence for real-world impact

We bring together a unique combination of end-to-end data, scalable digital tools, and AI-powered analytics all under one roof, rooted in behavioral health expertise.

Real-world
evidence

Enabling life sciences discovery with NeuroBlu, a seamless data and analytics platform

Learn More

AI-powered analytics

Proprietary AI/ML approaches designed specifically for behavioral health

Learn More

Specialty EHR & digital solutions

Solutions that reach the whole ecosystem, from specialty EHR to patient-facing tools

Learn More

Solutions

Ecosystem of solutions to improve behavioral health

Real-world evidence platform

Code Templates

Analytics Tools

Research-Grade EHR

1,215,000,000+

rows of behavioral data

1,400,000+

patients

20+

years of longitudinal data

30+

geographically diverse health systems

NeuroBlu enables users to access the most robust proprietary behavioral health dataset of its kind with structured outcome measures and seamless AI-powered analytic tools.

learn more

Learn More

Code Templates

Analytics Tools

Research-Grade EHR

Information on a wide variety of conditions, such as:

Substance use disorders: 255k+ patients

Major depressive disorder: 251k+ patients

Bipolar disorder: 134k+ patients

Attention-deficit/hyperactivity disorder: 82k+ patients

Post-traumatic stress disorder: 63k+ patients

Schizoaffective disorder: 34k+ patients

Schizophrenia: 33k+ patients

Borderline personality disorder: 19k+ patients

Autism spectrum disorder: 16k+ patients

Access to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:

Substance use disorders: 255k+ patients

Major depressive disorder: 251k+ patients

Bipolar disorder: 134k+ patients

Attention-deficit/hyperactivity disorder: 82k+ patients

Post-traumatic stress disorder: 63k+ patients

Schizoaffective disorder: 34k+ patients

Schizophrenia: 33k+ patients

Borderline personality disorder: 19k+ patients

Autism spectrum disorder: 16k+ patients

Access to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:

Substance use disorders: 255k+ patients

Major depressive disorder: 251k+ patients

Bipolar disorder: 134k+ patients

Attention-deficit/hyperactivity disorder: 82k+ patients

Post-traumatic stress disorder: 63k+ patients

Schizoaffective disorder: 34k+ patients

Schizophrenia: 33k+ patients

Borderline personality disorder: 19k+ patients

Autism spectrum disorder: 16k+ patients

Behavioral Health Conditions, including

Behavioral Health Assessments

Pharmacological Treatments

Information on a wide variety of conditions.

Substance use disorders: 255k+ patients

Major depressive disorder: 251k+ patients

Bipolar disorder: 134k+ patients

Attention-deficit/hyperactivity disorder: 82k+ patients

Post-traumatic stress disorder: 63k+ patients

Schizoaffective disorder: 34k+ patients

Schizophrenia: 33k+ patients

Borderline personality disorder: 19k+ patients

Autism spectrum disorder: 16k+ patients

Access to behavioral health assessments, enabling researchers to study disease severity and outcomes.

Clinical Global Impressions (CGI-I/CGI-S)

Columbia-Suicide Severity Rating Scale (C-SSRS)

Patient Health Questionnaire-9 (PHQ-9)

The Daily Living Activities–20 (DLA-20)

The Quick Inventory of Depressive Symptomatology (QIDS)

Brief Bipolar Disorder Symptom Scale (BDSS)

Positive Symptom Rating Scale (PSRS)

Brief Negative Symptom Assessment (BNSA)

Global Assessment of Functioning (GAF)

Access to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry.

Antidepressants

Antipsychotics

Anxiolytics

Hypnotics and sedatives

Mood stabilizers

Psycholeptics

Psychostimulants

Learn More

Explore Other Products

View all

HolCare EHR+ is a cloud-based, state-of-the-art electronic health records platform for behavioral health with innovative features such as fully integrated measurement-based care.

The Management and Supervision Tool (MaST) is a decision support tool which uses predictive analytics to enable healthcare providers to prioritize people at risk of mental health crisis, improving caseload management, use of resources and patient outcomes.